Form 4: Cytek Biosciences Director Jack Ball Reports Acquisition of Restricted Stock Units and Stock Options

Director Jack Ball reports acquisition of restricted stock units and stock options in Cytek Biosciences.

Summary

• On June 5, 2024, Jack Ball, a director of Cytek Biosciences, acquired 15,706 Restricted Stock Units (RSUs) and 23,076 stock options.
• The RSUs will vest on June 5, 2025, and each RSU represents the right to receive one share of Cytek Biosciences common stock.
• The stock options, with an exercise price of $5.73, were also granted on June 5, 2024, and expire on June 5, 2034.
• Following these transactions, Ball directly owns 15,706 RSUs and 23,076 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock options and RSUs, which is a common practice for director compensation.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of compensation packages for directors and executives in publicly traded biotechnology companies.
• Companies like Illumina, Thermo Fisher Scientific, and Danaher also utilize similar equity-based compensation to align management interests with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The acquisition of equity by a director can align their interests with those of shareholders.

Key Dates